Table 2 Patient characteristics
Level 1 (n = 3) n (%) | Level 2 (n = 3) n (%) | Level 3 (n = 6) n (%) | Total (n = 12) n (%) | ||
|---|---|---|---|---|---|
Age | Median | 62 | 67 | 64.5 | 64.5 |
Range | 47–68 | 62–79 | 47–80 | 47–80 | |
PS | 0 | 3 | 3 | 5 | 11 (91.7) |
1 | 0 | 0 | 1 | 1 (8.3) | |
2 | 0 | 0 | 0 | 0 (0) | |
TNM staging | Stage II | 1 | 1 | 1 | 3 (25.0) |
Stage IIIA | 0 | 0 | 3 | 3 (25.0) | |
Stage IIIB | 1 | 1 | 0 | 2 (16.7) | |
Stage IVA | 0 | 0 | 0 | 0 (0) | |
Stage IVB | 1 | 1 | 2 | 4 (33.3) | |
Virus infection | HBV | 2 | 2 | 3 | 7 (58.3) |
HCV | 1 | 1 | 1 | 3 (25.0) | |
Non-B, non-C | 0 | 0 | 2 | 2 (16.7) | |
Child–Pugh score | 5 | 3 | 2 | 2 | 7 (58.3) |
6 | 0 | 1 | 2 | 3 (25.0) | |
7 | 0 | 0 | 2 | 2 (16.7) | |
Extrahepatic metastasis | No | 2 | 2 | 4 | 8 (66.7) |
Yes | 1 | 1 | 2 | 4 (33.3) | |
History of sorafenib | No | 2 | 2 | 3 | 7 (58) |
Yes | 1 | 1 | 2 | 5 (42) | |
History of TACE | No | 0 | 0 | 1 | 1 (8.3) |
Yes | 3 | 3 | 5 | 11 (91.7) |